☆ 4.6 Review

Current status of locally advanced rectal cancer therapy and future prospects

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Immunology

Cancer organoid co-culture model system: Novel approach to guide precision medicine

Jin Yuan et al.

Summary: Three-dimensional cancer organoids derived from self-organizing cancer stems faithfully mimic the structure, features, and genetic signatures of tumors. Co-culture models involving immune cells or fibroblasts provide a means to investigate the tumor microenvironment and molecular interactions, potentially benefiting cancer research and precision medicine. However, the lack of a complete tumor microenvironment remains a major limitation that needs to be addressed for further improvements.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Oncology

A Review of Circulating Tumor DNA as a Biomarker Guide for Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer

Jehan Yahya et al.

Summary: Non-operative management is a popular approach for locally advanced rectal cancer patients with no evidence of disease after neoadjuvant therapy, but high recurrence rates and distant metastases have emphasized the urgent need for robust biomarker strategies. This review summarizes recent advances in the use of cell-free (cf) and circulating tumor (ct) DNA as potential biomarkers to guide non-operative management strategies for LARC patients.

JOURNAL OF GASTROINTESTINAL CANCER (2023)

Add to Collection

Article Oncology

Patient-derived tumor organoids predict responses to irinotecan-based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer

Tao Lv et al.

Summary: Adding irinotecan to neoadjuvant chemoradiotherapy in locally advanced rectal cancer can increase the pathologic complete response rate but also lead to more toxicities. Patient-derived tumor organoids (PDTOs) can predict the sensitivity to irinotecan and the treatment response and survival outcomes.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Surgery

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Esmee A. Dijkstra et al.

Summary: This study analyzed the risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial. The results showed that total neoadjuvant treatment (TNT), while increasing the risk of locoregional recurrence (LRR), can still reduce disease-related treatment failure and distant metastases after 5 years.

ANNALS OF SURGERY (2023)

Add to Collection

Article Oncology

Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer

Lisa S. M. Hofste et al.

Summary: This study evaluated the role of circulating tumor DNA (ctDNA) in assessing disease after neoadjuvant therapy and surgery to optimize treatment choices. The results showed that the detection of ctDNA after neoadjuvant therapy and surgery was associated with poor progression-free survival. This suggests that the detection of ctDNA may be helpful in predicting treatment response and prognosis in patients with early-stage and locally advanced rectal cancer.

EJSO (2023)

Add to Collection

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Oxaliplatin-based adjuvant chemotherapy rather than fluorouracil-based chemotherapy in rectal cancer is more efficient to decrease distant metastasis and increase survival after preoperative chemoradiotherapy and surgery: a meta-analysis

Jin Ho Song et al.

Summary: The addition of oxaliplatin to adjuvant therapy for stage II-III rectal cancer following preoperative CRT and TME may increase disease-free survival without significant increases in toxicity, but not overall survival.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2022)

Add to Collection

Meeting Abstract Oncology

Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2

Thomas J. George et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles

Michael Koukourakis et al.

Summary: Tumor-draining lymph nodes (TDLNs) are crucial sites for anti-tumor immune responses. Radiotherapy can enhance the release of tumor antigens and activate the interferon type-I pathway, promoting the development of a 'radio-vaccination' effect. However, irradiation may also deplete immune cells in TDLNs, compromising immune response and treatment effectiveness. Re-evaluation and interventions to preserve and handle the functional state of TDLNs or other lymph nodes may have therapeutic importance.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2022)

Add to Collection

Review Oncology

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer

Gianluca Mauri et al.

Summary: Colorectal cancer is a prevalent and deadly cancer, and there is a clinical need for better patient selection for systemic treatments. Genotyping circulating tumour DNA is a potential method to personalize treatment and overcome limitations of traditional biopsy approaches. This review summarizes the evidence of ctDNA applicability in colorectal cancer and discusses ongoing clinical trials.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)

Jing Jin et al.

Summary: This study aimed to compare the efficacy of preoperative short-term radiotherapy followed by chemotherapy with a standard schedule of long-term chemoradiotherapy in patients with locally advanced rectal cancer. The results showed that the short-term radiotherapy and chemotherapy regimen was non-inferior to the standard regimen in terms of 3-year disease-free survival and had better overall survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

Julio Garcia-Aguilar et al.

Summary: This study demonstrates that organ preservation is achievable in patients with locally advanced rectal cancer treated with total neoadjuvant therapy, without a decrease in survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal

Edina Dizdarevic et al.

Summary: An individualized treatment approach is crucial for improving survival and quality of life in rectal cancer, with circulating tumor DNA (ctDNA) showing promise as a useful tool for stratifying patients. However, current results are conflicting and lack standardization, highlighting the need for further studies to address bias and heterogeneity in reporting. Despite an association between ctDNA status and outcome, the field of research is still new with limited dedicated studies, underscoring the importance of standardization in ctDNA research for future advancements.

CANCERS (2022)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer

Andrea Cercek et al.

Summary: This study found that mismatch repair-deficient, locally advanced rectal cancer is highly sensitive to PD-1 blockade. Additionally, no adverse events of grade 3 or higher have been reported, and no cases of progression or recurrence have been observed. Longer follow-up is needed to assess the duration of response.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer et al.

Summary: The RAPIDO trial aimed to reduce systemic relapses in locally advanced rectal cancer through short-course radiotherapy, chemotherapy, and delayed surgery. Results showed a decreased probability of disease-related treatment failure in the experimental group compared to standard care, with diarrhea being the most common adverse event and neurological toxicity being prominent in the standard care group during adjuvant chemotherapy.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Tailored total neoadjuvant therapy for locally advanced rectal cancer: One size may not fit for all!

Leyla Ozer et al.

Summary: Current neoadjuvant protocols have benefits for local control in most patients with locally advanced rectal cancer. However, total neoadjuvant therapy requires further advances to address uncertainties such as patient selection criteria and the optimal sequence and type of chemotherapy and radiotherapy.

COLORECTAL DISEASE (2021)

Add to Collection

Article Oncology

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer

Zhenyu Lin et al.

Summary: The study found that preoperative short-course radiotherapy combined with CAPOX and camrelizumab followed by delayed surgery showed a favorable pathological complete response rate in locally advanced rectal cancer patients, especially in proficient MMR tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy et al.

Summary: In patients with cT3 or cT4 M0 rectal cancer, intensifying chemotherapy with FOLFIRINOX before preoperative chemoradiotherapy significantly improved disease-free survival outcomes and reduced neurotoxicity. Thus, the PRODIGE 23 results have the potential to impact clinical practice.

LANCET ONCOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

An update on the use of immunotherapy in patients with colorectal cancer

Mike Nguyen et al.

Summary: Immunotherapy has become a standard of care for some CRC patients with MSI. While overall survival data are still pending, the promise of profound and durable responses is highly anticipated. The lack of efficacy in MSS CRC is disappointing and strategies to convert these 'cold' tumors are needed.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Oncology

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)

A. Bapsi Chakravarthy et al.

ONCOLOGIST (2020)

Add to Collection

Article Oncology

Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma

Ali Shamseddine et al.

RADIATION ONCOLOGY (2020)

Add to Collection

Review Oncology

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer

Federica Papaccio et al.

CANCERS (2020)

Add to Collection

Article Multidisciplinary Sciences

Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

Tetsuro Tominaga et al.

PLOS ONE (2019)

Add to Collection

Article Oncology

Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12

Emmanouil Fokas et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

Yanhong Deng et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma The GEMCAD 1402 Randomized Clinical Trial

Carlos Fernandez-Martos et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Oncology

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial

Yong Sang Hong et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Cell Biology

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

Salo N. Ooft et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Add to Collection

Article Oncology

Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy

J. Joshua Smith et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Oncology

Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B plus (GrzB) cytotoxic T-cells in rectal cancer

Armin Jarosch et al.

ONCOIMMUNOLOGY (2018)

Add to Collection

Review Oncology

The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision

Susana Rosello et al.

CANCER TREATMENT REVIEWS (2018)

Add to Collection

Article Oncology

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03)

Carmine Pinto et al.

ONCOLOGIST (2018)

Add to Collection

Article Oncology

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial

Johan Erlandsson et al.

LANCET ONCOLOGY (2017)

Add to Collection

Review Oncology

Integrating liquid biopsies into the management of cancer

Giulia Siravegna et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Add to Collection

Review Gastroenterology & Hepatology

A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis

Fahima Dossa et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Systemic Immunity Is Required for Effective Cancer Immunotherapy

Matthew H. Spitzer et al.

CELL (2017)

Add to Collection

Article Oncology

Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study

K. Bujko et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Oncology

Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis

Andrew G. Renehan et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features

Ramon Salazar et al.

BMC CANCER (2015)

Add to Collection

Review Oncology

Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data

Anne J. Breugom et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study

Ane L. Appelt et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

Claus Roedel et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial

A. J. Breugom et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Oncology

Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study

Fiona G. M. Taylor et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Medicine, General & Internal

The life and legacy of William Ernest Miles (1869-1947): a tribute to an admirable surgeon

Fábio Guilherme Campos

Revista da Associacao Medica Brasileira (2013)

Add to Collection

Article Surgery

Neoadjuvant Radiotherapy for Rectal Cancer: Adherence to Evidence-Based Guidelines in Clinical Practice

Timothy L. Fitzgerald et al.

WORLD JOURNAL OF SURGERY (2013)

Add to Collection

Article Oncology

Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04

Samuel Y. Ngan et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

BEVACIZUMAB, CAPECITABINE, AMIFOSTINE, AND PREOPERATIVE HYPOFRACTIONATED ACCELERATED RADIOTHERAPY (HYPOARC) FOR RECTAL CANCER: A PHASE II STUDY

Michael I. Koukourakis et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)

Add to Collection

Article Oncology

Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer

Monique Maas et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial

Willem van Gijn et al.

LANCET ONCOLOGY (2011)

Add to Collection

Article Oncology

PHASE II TRIAL OF NEOADJUVANT BEVACIZUMAB, CAPECITABINE, AND RADIOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER

Christopher H. Crane et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)

Add to Collection

Article Surgery

The Natural History of Rectal Cancer 1908-2008: The Evolving Treatment of Rectal Cancer into the Twenty-First Century

Warren E. Enker

SEMINARS IN COLON AND RECTAL SURGERY (2010)

Add to Collection

Article Oncology

Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

Mark S. Roh et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

David Sebag-Montefiore et al.

LANCET (2009)

Add to Collection

Article Medicine, General & Internal

Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study

G. Brown et al.

BRITISH MEDICAL JOURNAL (2006)

Add to Collection

Article Oncology

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers:: Results of FFCD 9203

Jean-Pierre Gerard et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection

Article Surgery

Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer

K. Bujko et al.

BRITISH JOURNAL OF SURGERY (2006)

Add to Collection

Article Medicine, General & Internal

Chemotherapy with preoperative radiotherapy in rectal cancer

Jean-Francois Bosset et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Article Surgery

Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy - Long-term results

A Habr-Gama et al.

ANNALS OF SURGERY (2004)

Add to Collection

Article Medicine, General & Internal

Preoperative versus postoperative chemoradiotherapy for rectal cancer

R Sauer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

Article Medicine, General & Internal

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer

E Kapiteijn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

Add to Collection

Article Oncology

Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02

N Wolmark et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.